oncotype score calculator

Use this tool to interpret an existing Oncotype DX Recurrence Score or generate an educational estimate when a lab score is not available.

If you already have a Recurrence Score (0–100), enter it here:

If this field is filled, the calculator will interpret this value directly.

Or estimate from clinicopathologic factors

Age (years)

Tumor size (cm)

Tumor grade

Lymph node status

ER status

PR expression level

HER2 status

Ki-67 (%)

Lymphovascular invasion (LVI)

Menopausal status

Medical disclaimer: This page is for education only and does not produce an official Oncotype DX test result. Treatment decisions should always be made with your oncology team.

What is the Oncotype DX Recurrence Score?

The Oncotype DX Breast Recurrence Score is a genomic assay used in certain people with early-stage breast cancer, most commonly hormone receptor-positive (HR+), HER2-negative disease. It analyzes expression of a panel of tumor genes and reports a number from 0 to 100. That score helps estimate recurrence risk and, in many situations, helps guide whether chemotherapy may add benefit beyond endocrine therapy.

How this oncotype score calculator works

This calculator provides two useful pathways:

Score interpretation mode: If you already have your official Recurrence Score from pathology, enter it directly and get a quick category summary.
Educational estimate mode: If you do not have a genomic assay result, the tool creates a clinicopathologic risk estimate based on age, tumor size, grade, nodal status, receptor profile, Ki-67, and LVI.

Important: a clinicopathologic estimate is not the same as gene-expression testing and should never replace clinical judgment.

General interpretation ranges

Commonly referenced score bands

0–10: Lower genomic risk profile; endocrine therapy alone is often considered in many contexts.
11–25: Intermediate range; treatment decisions are individualized by age, menopausal status, node status, and patient preferences.
26+: Higher genomic risk profile; many patients may be advised to discuss chemotherapy benefit more strongly.

These ranges are educational summaries only. Real-world decisions vary by updated evidence, staging details, and physician interpretation.

When an Oncotype-style approach is most relevant

Oncotype-based clinical pathways are often discussed in patients with:

Early-stage invasive breast cancer
ER-positive / HER2-negative biology
Node-negative disease or limited node-positive disease (depending on current guideline context)
Uncertainty about net chemotherapy benefit

Practical tips before using any recurrence score tool

1) Confirm pathology details

Make sure receptor status, grade, and nodal findings are final and not preliminary.

2) Use the exact report value when available

If your official report provides a Recurrence Score, that number should take priority over any estimated model.

3) Discuss personal factors

Fertility goals, comorbidities, bone health, and treatment tolerance all matter in shared decision-making.

Questions to ask your oncologist

Is my cancer profile the type where Oncotype DX is validated?
How does my score change recommended treatment in my specific case?
What is the expected absolute chemotherapy benefit for me?
How do menopausal status and node status affect interpretation?
What are alternatives if genomic testing is unavailable?

Bottom line

An oncotype score calculator is most valuable as an education and communication aid. It can help you understand risk categories and prepare for oncology visits, but it cannot replace genomic lab testing, multidisciplinary review, or personalized medical advice. Use the calculator above to get a structured starting point, then review every result with your care team.